Scholarlink

<p>Neuroblastoma is among the most biologically heterogeneous pediatric malignancies, and amplification of the MYCN oncogene remains a defining molecular hallmark of high-risk disease. Although MYCN amplification is firmly established as a powerful prognostic biomarker and oncogenic driver, copy number alone does not fully explain the marked variability in transcriptional output, cellular phenotype, therapeutic response, and clinical outcome observed among MYCN-amplified tumors. Recent advances in structural genomics, epigenomics, chromatin biology, and single-cell analysis have revealed that MYCN activity is shaped by the architecture of amplified DNA, enhancer composition, three-dimensional chromatin organization, developmental cell state, cooperating genomic alterations, and adaptive interactions with the tumor microenvironment. This review integrates these emerging concepts with established MYCN biology. It examines the molecular regulation and structural evolution of MYCN amplicons; the contribution of extrachromosomal DNA, homogeneously staining regions, and enhancer hijacking; cooperating alterations such as ALK activation, 1p36 loss, and 17q gain; alternative high-risk contexts characterized by 11q deletion or ATRX-associated alternative lengthening of telomeres; and the influence of adrenergic-mesenchymal plasticity, signaling crosstalk, metabolism, DNA damage responses, and immune regulation. The review further evaluates therapeutic strategies that target MYCN directly or exploit its transcriptional, epigenetic, metabolic, and replication-stress dependencies, with particular emphasis on resistance mechanisms, patient-selection biomarkers, and rational combination therapy. Collectively, current evidence supports a context-dependent model in which MYCN amplification establishes oncogenic potential, whereas genomic architecture, epigenetic regulation, developmental identity, and adaptive signaling determine tumor behavior. This framework provides a basis for next-generation biomarker development and precision therapeutic strategies in high-risk neuroblastoma. By advancing molecular understanding, therapeutic development, and knowledge dissemination in pediatric cancer, this article aligns with United Nations Sustainable Development Goal 3 (Good Health and Well-Being) and Goal 4 (Quality Education).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

MYCN amplification in neuroblastoma: established paradigms, prognostic consensus, and emerging biological paradoxes

  • 期刊论文

  • 发表日期：

    2026年8月4日

查看全文
  • Udayan Bhattacharya

摘要

Neuroblastoma is among the most biologically heterogeneous pediatric malignancies, and amplification of the MYCN oncogene remains a defining molecular hallmark of high-risk disease. Although MYCN amplification is firmly established as a powerful prognostic biomarker and oncogenic driver, copy number alone does not fully explain the marked variability in transcriptional output, cellular phenotype, therapeutic response, and clinical outcome observed among MYCN-amplified tumors. Recent advances in structural genomics, epigenomics, chromatin biology, and single-cell analysis have revealed that MYCN activity is shaped by the architecture of amplified DNA, enhancer composition, three-dimensional chromatin organization, developmental cell state, cooperating genomic alterations, and adaptive interactions with the tumor microenvironment. This review integrates these emerging concepts with established MYCN biology. It examines the molecular regulation and structural evolution of MYCN amplicons; the contribution of extrachromosomal DNA, homogeneously staining regions, and enhancer hijacking; cooperating alterations such as ALK activation, 1p36 loss, and 17q gain; alternative high-risk contexts characterized by 11q deletion or ATRX-associated alternative lengthening of telomeres; and the influence of adrenergic-mesenchymal plasticity, signaling crosstalk, metabolism, DNA damage responses, and immune regulation. The review further evaluates therapeutic strategies that target MYCN directly or exploit its transcriptional, epigenetic, metabolic, and replication-stress dependencies, with particular emphasis on resistance mechanisms, patient-selection biomarkers, and rational combination therapy. Collectively, current evidence supports a context-dependent model in which MYCN amplification establishes oncogenic potential, whereas genomic architecture, epigenetic regulation, developmental identity, and adaptive signaling determine tumor behavior. This framework provides a basis for next-generation biomarker development and precision therapeutic strategies in high-risk neuroblastoma. By advancing molecular understanding, therapeutic development, and knowledge dissemination in pediatric cancer, this article aligns with United Nations Sustainable Development Goal 3 (Good Health and Well-Being) and Goal 4 (Quality Education).